Pink SheetAgenus Inc. got an unwelcome surprise from the US Food and Drug Administration, which recommended against the company filing for accelerated approval for the combination of its CTLA-4-targeting monoc
Pink SheetRare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions
ScripAgenus Inc. got an unwelcome surprise from the US Food and Drug Administration as the agency recommended against the company filing for accelerated approval for the combination of its CTLA-4-targetin
ScripLigand Pharmaceuticals, Inc. has made its second major oncology investment in two months with the acquisition of Apeiron Biologics AG and the Austrian biotech’s royalty rights for Qarziba (dinutuxi